Cathie Wood’s ARK Investment Management recently made some changes to its portfolio, selling off its shares in Moderna while increasing its holdings in Intellia and Tempus stock. The move comes as part of ARK’s strategy to capitalize on emerging opportunities in the market.
Moderna, a biotechnology company known for its COVID-19 vaccine, saw its stock being sold by ARK. On the other hand, ARK decided to buy more shares of Intellia, a biopharmaceutical company focused on developing gene editing therapies, and Tempus, a technology company specializing in data-driven precision medicine.
These decisions reflect ARK’s belief in the potential growth of Intellia and Tempus, as they continue to innovate and make advancements in their respective fields. By selling off Moderna, ARK is reallocating its resources to companies that it believes have greater potential for long-term success.
Overall, Cathie Wood’s ARK Investment Management is constantly looking for opportunities to optimize its portfolio and position itself for success in the ever-changing market. The recent changes in its holdings demonstrate ARK’s commitment to staying ahead of the curve and investing in companies with promising futures.